Literature DB >> 31337297

Risk of Intracerebral Hemorrhage and Mortality After Convexity Subarachnoid Hemorrhage in Cerebral Amyloid Angiopathy.

Lionel Calviere1,2, Alain Viguier1,2, Sofia Patsoura3, Vanessa Rousseau4,5, Jean-François Albucher1,2, Mélanie Planton1,2, Jérémie Pariente1,2, Christophe Cognard3, Jean-Marc Olivot1,2, Fabrice Bonneville3,2, Nicolas Raposo1,2.   

Abstract

Background and Purpose- Convexity subarachnoid hemorrhage (cSAH) is an increasingly recognized presentation of cerebral amyloid angiopathy (CAA), usually revealed by transient symptoms, but data on its outcome are limited. We compared the risk of future intracerebral hemorrhage (ICH), cSAH, and death in patients with CAA after cSAH and after lobar ICH. Methods- Consecutive patients with probable CAA, based on the Boston criteria, presenting with cSAH (CAA-cSAH) or lobar ICH (CAA-ICH) were included. We obtained baseline clinical and magnetic resonance imaging data and follow-up information. Univariable and multivariable analyses were used to compare incidence rate for symptomatic ICH, symptomatic cSAH, and late-death (beyond 30 days) between patients with CAA-cSAH and CAA-ICH. Results- Among 105 patients (mean age, 76.7±7.5 years) enrolled, 44 participants presented with CAA-cSAH and 61 with CAA-ICH. The median follow-up was 22.2 months (interquartile range, 12.6-34.4). The symptomatic ICH rate (per person-year) was 10.5% (95% CI, 5.6-19.4) in patients with CAA-cSAH compared with 8.5% (95% CI, 4.4-16.4) in those with CAA-ICH (adjusted hazard ratio, 1.05; 95% CI, 0.32-3.43). The annual incidence rates of symptomatic cSAH (9.9% versus 3.8%; adjusted hazard ratio, 1.77; 95% CI, 0.43-7.28) and death (9.5% versus 17.8%; adjusted hazard ratio, 0.56; 95% CI, 0.22-1.43) were not significantly different between patients with CAA-cSAH and those with CAA-ICH. Conclusions- Patients with CAA-related cSAH have a poor outcome, with similar high risk of future ICH and long-term mortality than CAA patients after lobar ICH. Our findings may have important prognostic implication and guide management of patients with cSAH in CAA.

Entities:  

Keywords:  cerebral amyloid angiopathy; intracerebral hemorrhage; outcome; subarachnoid hemorrhage

Year:  2019        PMID: 31337297     DOI: 10.1161/STROKEAHA.119.026244

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  4 in total

1.  A nomogram to predict the risk of postoperative intracranial rebleeding in patients with spontaneous intracranial hematoma.

Authors:  Junhua Yang; Yang Liu; Qingyuan Liu; Kaiwen Wang; Shaohua Mo; Maogui Li; Jun Wu; Pengjun Jiang; Shuzhe Yang; Rui Guo; Yi Yang; Jiaming Zhang; Yong Cao; Shuo Wang
Journal:  Neurosurg Rev       Date:  2021-10-29       Impact factor: 3.042

Review 2.  Chinese Stroke Association guidelines for clinical management of cerebrovascular disorders: executive summary and 2019 update of clinical management of spontaneous subarachnoid haemorrhage.

Authors:  Yu-Xiang Gu; Qiang Dong; Yi Dong; Zhen-Ni Guo; Qi Li; Wei Ni; Hongqiu Gu
Journal:  Stroke Vasc Neurol       Date:  2019-12-18

Review 3.  Taxifolin: A Potential Therapeutic Agent for Cerebral Amyloid Angiopathy.

Authors:  Satoshi Saito; Masashi Tanaka; Noriko Satoh-Asahara; Roxana Octavia Carare; Masafumi Ihara
Journal:  Front Pharmacol       Date:  2021-02-12       Impact factor: 5.810

4.  Early MRI imaging and follow-up study in cerebral amyloid angiopathy.

Authors:  Shan-Chun Zhang; Jian-Jun Jia; Heng-Li Zhao; Bo Zhou; Wei Wang; Xiang-Hui Lu; Hao Wang; Zhen-Fu Wang; Wei-Ping Wu
Journal:  Open Med (Wars)       Date:  2021-02-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.